Biospecimens are invaluable in pinpointing de novo therapeutic drug targets; they are also a critical tool for the identification of novel cancer resistance mechanisms and oncogenic pathways. Here, we highlight keys to selecting the biospecimens best suited to drive success for IO research and development.
Rare disease trials are inherently complex. Pediatric rare disease trials compound it further. Having supported 150+ rare disease trials, many for pediatric indications, our Precision experts have detailed advice. Here, Traci Fulton, Executive Director, Project Management, addresses pediatric-specific hurdles and provides strategies to overcome them, including lessons learned during COVID-19.
Electronic data capture (EDC) systems are essential repositories for patient data in clinical trials. As such, their go-live date impacts trial-wide scheduling. In this article, Michelle Martell, Executive Director, Data Management at Precision for Medicine, shares the factors that drive EDC timelines, insights into key aspects of EDC design and build, and vital steps sponsors can take to optimize workflow.
On-Demand Webinar: NAb vs TAb Assays in Gene Therapy Development: Key Considerations For Assessing Immunogenicity
With pre-existing immunity to viral vectors presenting a major challenge to the delivery of life-changing gene therapies, developing an assay to assess humoral immunogenicity. But, how can you determine whether a NAb or Tab assay is best? Deb Phippard, PhD, Chief Science Officer, and Travis Harrison, PhD, Vice President, Bioassay Solutions, Precision for Medicine, offer guidance in this must-see webinar.
As the demand for COVID-19 diagnostic tests soar, the FDA guidelines around emergency-use authorization continue to shift. In this 30-minute webinar, Jo-Ann Gonzales, RAC, Director, IVD Regulatory & Quality Consulting, Precision for Medicine, shares what has changed, provides 2 example case studies, and offers 5 key takeaways for those seeking FDA approval.
When a network of specialty labs use individual data formats and annotations, the result is translational data chaos—and deep frustration for the researchers who have to manually curate and prepare data. In this 30-minute webinar, QuartzBio experts demonstrate how integrating exploratory biomarker, PK, and clinical data silos in a translational hub enables teams to interrogate trends and identify insights as data is generated on-study.